EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elevated IL-6 and Tumor Necrosis Factor-α in Immune Checkpoint Inhibitor Myocarditis

Abdelrahman Ali, Rebecca Caldwell iD, Gaspar Pina, Noah Beinart iD, Garrett Jensen, Syed Wamique Yusuf, Efstratios Koutroumpakis, Ihab Hamzeh, Shaden Khalaf, Cezar Iliescu iD, Anita Deswal, Nicolas L Palaskas iD

Diseases · 03.05.2024 · 12 (5) · 88

DOI: 10.3390/diseases12050088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diseases, online erschienen am 03.05.2024. Verfasst von Abdelrahman Ali und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1451, Houston, T…. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Prevention & Research Institute of Texas (CPRIT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The impact of peripheral cytokine levels on the prognosis and treatment of immune checkpoint inhibitor (ICI) myocarditis has not been well studied.

Objectives

This study aimed to identify cytokines that can prognosticate and direct the treatment of ICI myocarditis.

Methods

This was a single-center, retrospective cohort study of patients with ICI myocarditis who had available peripheral cytokine levels between January 2011 and May 2022. Major adverse cardiovascular events (MACEs) were defined as a composite of heart failure with/without cardiogenic shock, arterial thrombosis, life-threatening arrhythmias, pulmonary embolism, and sudden cardiac death.

Results

In total, 65 patients with ICI myocarditis had cytokine data available. Patients were mostly males (70%), with a mean age of 67.8 ± 12.7 years. Interleukin (IL)-6 and tumor necrosis factor-α (TNF-α) were the most common cytokines to be elevated with 48/65 (74%) of patients having a peak IL-6 above normal limits (>5 pg/mL) and 44/65 (68%) of patients with peak TNF-α above normal limits (>22 pg/mL). Patients with elevated peak IL-6 had similar 90-day mortality and MACE outcomes compared to those without (10.4% vs. 11.8%, p = 0.878 and 8.8% vs. 17.7%, p = 0.366, respectively). Similarly, those with elevated peak TNF-α had similar 90-day mortality and MACEs compared to those without (29.6% vs. 14.3%, p = 0.182 and 13.6% vs. 4.8%, p = 0.413, respectively). Kaplan–Meier survival analysis also showed that there was not a significant difference between MACE-free survival when comparing elevated and normal IL-6 and TNF-α levels (p = 0.182 and p = 0.118, respectively). MACEs and overall survival outcomes were similar between those who received infliximab and those who did not among all patients and those with elevated TNF-α (p-value 0.70 and 0.83, respectively).

Conclusion

Peripheral blood levels of IL-6 and TNF-α are the most commonly elevated cytokines in patients with ICI myocarditis. However, their role in the prognostication and guidance of immunomodulatory treatment is currently limited.

Schlagwörter

Stichwörter der Autor:innen

CardiotoxicityCytokinesImmunotherapyMyocarditis

Autor:innen und Institutionen

  • Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1451, Houston, TX 77030, USA.
  • Texas A&M College of Medicine, Center for Genomics and Precision Medicine, Houston, TX 77030, USA.

ORCID-Profile: Rebecca Caldwell, Noah Beinart, Cezar Iliescu, Nicolas L Palaskas

Förderung

  • NCI NIH HHS
  • Cancer Prevention & Research Institute of Texas (CPRIT)

Zitieren

APA

Ali, A., Caldwell, R., Pina, G., Beinart, N., Jensen, G., Yusuf, S. W., Koutroumpakis, E., Hamzeh, I., Khalaf, S., Iliescu, C., Deswal, A., & Palaskas, N. L. (2024). Elevated IL-6 and Tumor Necrosis Factor-α in Immune Checkpoint Inhibitor Myocarditis. Diseases, 12(5), 88. https://doi.org/10.3390/diseases12050088

Vancouver

Ali A, Caldwell R, Pina G, Beinart N, Jensen G, Yusuf SW, et al. Elevated IL-6 and Tumor Necrosis Factor-α in Immune Checkpoint Inhibitor Myocarditis. Diseases. 2024;12(5):88. doi:10.3390/diseases12050088

BibTeX
@article{Ali2024,
  author = {Ali, Abdelrahman and Caldwell, Rebecca and Pina, Gaspar and Beinart, Noah and Jensen, Garrett and Yusuf, Syed Wamique and Koutroumpakis, Efstratios and Hamzeh, Ihab and Khalaf, Shaden and Iliescu, Cezar and Deswal, Anita and Palaskas, Nicolas L},
  title = {Elevated IL-6 and Tumor Necrosis Factor-α in Immune Checkpoint Inhibitor Myocarditis},
  journal = {Diseases},
  year = {2024},
  volume = {12},
  number = {5},
  pages = {88},
  doi = {10.3390/diseases12050088}
}
Kostenlos starten →